Xanthos Theodoros, Ekmektzoglou Konstantinos A, Papadimitriou Lila
Department of Experimental Surgery and Surgical Research N.S.Christeas, Athens School of Medicine, Athens, Greece.
Int J Cardiol. 2008 Feb 29;124(2):139-48. doi: 10.1016/j.ijcard.2007.04.029. Epub 2007 Jun 13.
Silent myocardial ischemia (SMI) is a relatively common, yet poorly understood, clinical entity. The most accurate means of detecting SMI and the precise treatment endpoints remain unclear. However, the presence of SMI correlates with the likelihood of future adverse cardiac events. Evidence suggests that patients at high risk of severe cardiac ischemia, even with the absence of symptoms, derive the greatest benefit from an aggressive diagnostic and therapeutic approach. This paper is giving a detailed review of SMI in regards to specific patient subgroups, i.e. populations with diabetes mellitus, hypertension, elderly patients, post-revascularization patients, women, the suggested screening procedures for each subgroup, as well as the emersion of new markers for the selection of high-risk patients for screening.
无症状心肌缺血(SMI)是一种相对常见但了解甚少的临床病症。检测SMI的最准确方法以及精确的治疗终点仍不明确。然而,SMI的存在与未来发生不良心脏事件的可能性相关。有证据表明,即使没有症状,处于严重心肌缺血高风险的患者从积极的诊断和治疗方法中获益最大。本文详细综述了特定患者亚组中的SMI,即糖尿病患者群体、高血压患者群体、老年患者、血管重建术后患者、女性患者,每个亚组的建议筛查程序,以及用于选择高危患者进行筛查的新标志物的出现情况。